We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M Turnover 44%
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+20.25%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$537M
AUM Growth
+$121M
Cap. Flow
+$4.8M
Cap. Flow %
0.89%
Top 10 Hldgs %
39.95%
Holding
98
New
28
Increased
18
Reduced
12
Closed
34
Avg Time Held Equity + Options
0.4 years
Top 10 Avg Time Held Equity + Options
0.2 years
Top 20 Avg Time Held Equity + Options
0.2 years
Avg Time Held Equity only
0.5 years
Top 10 Avg Time Held Equity only
0.1 years
Top 20 Avg Time Held Equity only
0.4 years

Sector Composition

Rank Sector Weight
1 Healthcare 69.32%
2 Miscellaneous 30.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$62.4M 11.63%
900,000
+300,000
+50% +$20.1M
2016 Q1
4 quarters
IWM icon
2
PUT
iShares Russell 2000 ETF
IWM
$75.6B
$34.4M 6.41%
+250,000
New +$34.2M
2017 Q1
0 quarters
SPY icon
3
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$791B
$23.6M 4.39%
+100,000
New +$23.2M
2017 Q1
0 quarters
DBVT icon
4
DBV Technologies
DBVT
$657M
$17.6M 3.28%
50,000
+17,500
+54% +$6.14M
2016 Q3
2 quarters
AVXS
5
DELISTED
AveXis
AVXS
$13.3M 2.48%
175,000
– –
2016 Q3
2 quarters
NBIX icon
6
Neurocrine Biosciences
NBIX
$16.9B
$13M 2.42%
+300,000
New +$12.9M
2017 Q1
0 quarters
CLVS
7
DELISTED
Clovis Oncology
CLVS
$12.7M 2.37%
200,000
-20,000
-9% -$1.22M
2016 Q1
4 quarters
BCRX icon
8
BioCryst Pharmaceuticals
BCRX
$1.95B
$12.6M 2.35%
1,500,000
+350,000
+30% +$2.43M
2016 Q2
3 quarters
SGEN
9
DELISTED
Seagen
SGEN
$12.6M 2.34%
200,000
+50,000
+33% +$3.12M
2016 Q4
1 quarter
ZBH icon
10
Zimmer Biomet
ZBH
$19.2B
$12.2M 2.28%
103,000
-30,900
-23% -$3.5M
2016 Q3
2 quarters
ACAD icon
11
Acadia Pharmaceuticals
ACAD
$3.34B
$12M 2.24%
350,000
+250,000
+250% +$8.82M
2016 Q3
2 quarters
BSX icon
12
Boston Scientific
BSX
$64B
$11.2M 2.09%
450,000
– –
2016 Q1
4 quarters
ONCE
13
DELISTED
Spark Therapeutics
ONCE
$10.7M 1.99%
200,000
+120,000
+150% +$7.12M
2016 Q4
1 quarter
XLRN
14
DELISTED
Acceleron Pharma
XLRN
$10.6M 1.97%
400,000
+360,000
+900% +$9.49M
2016 Q4
1 quarter
EPZM
15
DELISTED
Epizyme
EPZM
$10.3M 1.92%
600,000
+125,000
+26% +$1.66M
2016 Q4
1 quarter
AERI
16
CALL
DELISTED
Aerie Pharmaceuticals
AERI
$10M 1.86%
+220,000
New +$9.8M
2017 Q1
0 quarters
VRTX icon
17
Vertex Pharmaceuticals
VRTX
$138B
$9.8M 1.83%
+90,000
New +$7.92M
2017 Q1
0 quarters
IMMU
18
DELISTED
Immunomedics
IMMU
$9.7M 1.81%
1,500,000
-200,000
-12% -$1.01M
2016 Q2
3 quarters
MRK icon
19
Merck
MRK
$362B
$9.5M 1.78%
157,200
-78,600
-33% -$4.77M
2016 Q4
1 quarter
SPNC
20
CALL
DELISTED
Spectranetics
SPNC
$9.46M 1.76%
+325,000
New +$8.66M
2017 Q1
0 quarters
ELGX
21
DELISTED
Endologix
ELGX
$9.41M 1.75%
+130,000
New +$8.6M
2017 Q1
0 quarters
ENTA icon
22
Enanta Pharmaceuticals
ENTA
$317M
$9.24M 1.72%
+300,000
New +$9.34M
2017 Q1
0 quarters
NUVA
23
DELISTED
NuVasive
NUVA
$8.96M 1.67%
120,000
-30,000
-20% -$2.18M
2014 Q3
10 quarters
IOVA icon
24
Iovance Biotherapeutics
IOVA
$3.57B
$8.94M 1.67%
1,200,000
+225,000
+23% +$1.65M
2016 Q1
4 quarters
KDNY
25
DELISTED
Chinook Therapeutics
KDNY
$8.6M 1.6%
+160,000
New +$9.04M
2017 Q1
0 quarters

Similar funds

Ghost Tree Capital's Q1 2017 Portfolio in Review

As of Q1 2017, Ghost Tree Capital held 98 positions worth $537M, up 29% from $415M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Ghost Tree Capital's Q1 2017 filing shows 28 new, 18 increased, 12 reduced and 34 closed positions. Its largest new stake was Neurocrine Biosciences: 300,000 shares worth $13M. The largest sale was Abbott, an estimated $15.4M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 78% a quarter earlier, followed by Miscellaneous.

  • Ghost Tree Capital's largest Q1 2017 buy was Neurocrine Biosciences: 300,000 shares worth $13M.
  • Ghost Tree Capital added most to Acceleron Pharma in Q1 2017, an estimated $9.49M increase.
  • Ghost Tree Capital's biggest Q1 2017 reduction was Shire, cutting an estimated $12.2M.
  • Ghost Tree Capital fully exited Abbott in Q1 2017, selling an estimated $15.4M.
  • Ghost Tree Capital's ten largest holdings make up 40% of its $537M portfolio in Q1 2017.
  • Ghost Tree Capital opened 28 new positions and closed 34 in Q1 2017.
  • Ghost Tree Capital's portfolio value rose 29% quarter-over-quarter to $537M.

Based on Ghost Tree Capital's 13F filing for Q1 2017, filed 15 May 2017.